Inicio
Entrar
Ayuda
Buscar en este sitio:
Ensayos Registrados
Por tipo de intervención
Por estado de reclutamiento
Por promotor
Por fecha de registro
Búsqueda avanzada de ensayos
Proceso de Registro
Para registrar un ensayo
Formulario del Promotor
Formulario de ensayos del RPCEC
Para actualizar un ensayo registrado
Para reportar los resultados de un ensayo registrado
Inicio
|
Effect of dietary fiber consumption on health
View current
Revisiones
Comparando dos revisiones:
16 Mayo 2022 - 1:08pm
por Gladys
10 Diciembre 2024 - 9:42am
por kmunoz
próxima diferencia >
Cambios a
Record Verification Date
-
2022
/
05
/
16
+
2023
/
02
/
13
Cambios a
Next update date
-
2023
/
05
/
16
+
2024
/
02
/
13
Revisión de 10 Diciembre 2024 - 9:42am
Effect of dietary fiber consumption on health
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Acronym of Public Title:
FiberHealth
Scientific title:
Effect of dietary fiber consumption on body composition, gut microbiota and biochemical markers associated with metabolic state in overweight people: a pilot study
Secondary indentifying numbers:
25-2021-C
Issuing authority of the secondary identifying numbers:
Ethics Committee in Human Research, CES University
Primary sponsor:
VIDARIUM-Centro de Investigación en Nutrición, Salud y Bienestar.
Secondary sponsor:
Not applicable
Source(s) of monetary or material support:
VIDARIUM-Centro de Investigación en Nutrición, Salud y Bienestar, Grupo de investigación ICIF-Universidad del CES, Compañía de Galletas Noel S.A.S
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Only approved by Ethics Committees
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Katalina
Last name:
Munnoz-Durango
Medical Specialty :
Pharmaceutical chemistry, Diploma: Research and development of products to meet public health needs, PhD in Chemistry science
Affiliation:
VIDARIUM- Nutrition, Health and Wellness Research Center
Postal address:
Cl. 67 #52-20
City:
Medellin
País:
Colombia
Zip Code:
050010
Telephone:
+57-3006531404
Email address:
kmunoz@serviciosnutresa.com
kmunos@gmail.com
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Colombia
Clinical sites:
Medellín-Antioquia, Clínica Las Américas-AUNA, Doctor Juan Pablo Polanco (Physician, Internist)
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Pending
Date of first enrollment:
15/06/2022
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
Overweight individuals enrolled in a weight loss and cardiometabolic risk reduction program
Health condition(s) code:
Overweight
Intervention(s):
Dietary fiber (experimental group): Sachets of 2g compound by 1g of konjac glucomannan (dietary fiber) + 1g of dehydrated fruit, dissolved in 200mL of water before every meal (breakfast, lunch, and dinner; 3g/day of glucomannans; 6g/day of product) during 3 months. Dehydrated fruit (control group): Sachets of 2g of dehydrated fruit powder dissolved in 200mL of water before every meal (breakfast, lunch, and dinner; 6g/day of product) during 3 months.
Intervention code:
Dietary Fiber
Amorphophallus konjac
Placebos
Dietary Supplements
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
Weight (values expressed in kg measured with digital weighing scale). Measurement Time: At baseline and, 12 weeks.
Key secondary outcomes:
1- Body composition (Body fat (values expressed in g/cm2 measured with densimeter LUNAR Prodigy); lean mass (values expressed in g/cm2 measured with densimeter LUNAR Prodigy); bone mass (values expressed in g/cm2 measured with densimeter LUNAR Prodigy); bioimpedance (values expressed in % of fat measured with InBody770)). Measurement Time: At baseline and, 12 weeks. 2- Gut microbiome (gut microbiome composition (values expressed as abundance of 16S rRNA gene fragments obtained from sequencing the variable V4 region with Illumina MiSeq technology)). Measurement Time: At baseline and, 12 weeks. 3- Biochemical markers (Total cholesterol in plasma (values expressed in mg/dL determined by enzymatic assay of oxidized glucose; cholesterol LDL, HDL (values expressed in mg/dL determined by direct enzymatic method); triglycerides (values expressed in mg/dL determined by the enzymatic colorimetric test, Roche, Mannheim, Germany); glycemia (values expressed in mg/dL determined by enzymatic assay); fasting insulin (values expressed in µUI/mL measured by a chemo-luminescence immunoassay); glycosylated hemoglobin (values expressed in mmol/mol measured with HPLC, Premier Hb9210; Lab Care, UK); C-reactive protein (values expressed in mg/dL determined by immunoturbidimetric high-sensitivity assay, Roche Diagnostics Mannheim, Germany, Hitachi 902); IL-18 (values expressed in ng/mL measured by multianalyte immunoassay using xMAP from Luminex and reads obtained from multi analyzer Magpix, Luminex Corp., USA); Chemerin (values expressed in ng/mL measured by multianalyte immunoassay using xMAP from Luminex and reads obtained from multi analyzer Magpix, Luminex Corp., USA); LBP in plasma (values expressed in ng/mL measured by multianalyte immunoassay using xMAP from Luminex and reads obtained from multi analyzer Magpix, Luminex Corp., USA); oxysterols (values expressed in mg/dL measured with GC/MS); short fatty acids in plasma (values expressed in mg/dL measured with GC/MS); Peptides: AgRP/ART, adiponectin, leptin (values expressed in ng/mL measured by multianalyte immunoassay using xMAP from Luminex and reads obtained from multi analyzer Magpix, Luminex Corp., USA)). Measurement Time: At baseline and, 12 weeks. 4- Food consumption (values expressed in g recorded as 24-hour reminder format). Measurement Time: At baseline and 3, 6, and 12 weeks. 5- Blood pressure (values expressed in mm Hg measured with blood pressure monitor). Measurement Time: At baseline and, 12 weeks.
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
20 years
Maximum age:
50 years
Inclusion criteria:
1. Volunteers 2. age ≥ 20 and ≤ 50 3. BMI ≥27.0 and <35 kg/m2 4. With at least one of the following conditions: 4.1 Abdominal circumference ≥88 cm in women and ≥102 cm in men 4.2 Blood pressure ≥130/85 mm Hg (stage 1: 130-139 or 80-89 mm Hg) 4.3 HDL <40mg/dL (men) or <50 mg/dL (women) 4.4 triglycerides >150mg/dL 4.5 and/or fasting glucose ≥100 mg/dL
Exclusion criteria:
1. Heart attack 2. Congestive heart failure 3. Stroke 4. Arrhythmia 5. Cancer 6. Chronic renal failure 7. Liver disorders 8. Insomnia 9. Duodenal ulcer 10. Gastritis 11. Malabsorption disorders (in general, diagnosed with gastrointestinal diseases) 12. Dysautonomia (positive tilt test) 13. Autoimmune and/or rheumatologic 14. Psychiatric disorders. 15. Those who have medically prescribed metformin, anti-inflammatories, steroids, hypnotic drugs, antibiotics, antiparasitics, or laxatives. Women who become pregnant during the study. 16. Individuals who show intolerance or adverse effects to the consumption of soluble fiber (konjac glucomannan) during the intervention will be withdrawn from the study. Their data, however, will be included in the group of poorest outcome (intention to treat).
Type of population:
Adults
Type of participant:
Patients
Study design
Section to complete information about the characteristics of the study design.
Type study:
Interventional
Purpose:
Treatment
Allocation:
Randomized controlled trial
Masking:
Double Blind
Control group:
Placebo
Study design:
Parallel
Phase:
N/A
Target sample size:
40
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Vanessa
Last Name:
Corrales Agudelo
Specialty:
Nutritionist. Master in Basic Biomedical Sciences, emphasis in Nutritional Biochemistry
Affiliation:
VIDARIUM-Nutrition, Health and Wellness Research Center
Postal Address:
Cl. 67 #52-20
City:
Medellin
País:
Colombia
Zip Code:
050010
Telephone:
+57-3004369525
Email :
vcorrales@serviciosnutresa.com
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Katalina
Last Name:
Munnoz-Durango
Specialty:
Pharmaceutical chemistry, Diploma: Research and development of products to meet public health needs, PhD in Chemistry science
Affiliation:
VIDARIUM-Nutrition, Health and Wellness Research Center
Postal Address:
Cl. 67 #52-20
City:
Medellin
País:
Colombia
Zip Code:
050010
Telephone:
+57-3006531404
Email :
kmunoz@serviciosnutresa.com
kmunos@gmail.com
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
Yes
Description of Data Sharing Plan:
a. Data on the DNA sequences of the V4 region of the 16S rRNA gene of prokaryotes will be shared b. The data will be available when the results are published. c. The data can be obtained by downloading the data (FASTQ files) from the cloud (ex: NCBI-SRA or Github)
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
Institutional Committee of Ethics in Human Research Universidad CES
Status of evaluation:
Approved
Status of evaluation date of Ethic Committee:
12/07/2021
Postal address of Ethic Committee :
Calle 10 A #22-04, Medellín Colombia
Correo electrónico:
comiteeticahumanos@ces.edu.co
About study completion
Section to complete the data related to the study completion.
Study completion date:
30/06/2023
Date of available results:
20/12/2023
Date of first publication:
30/06/2024
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000406
Date of Registration in Primary Registry:
16/05/2022
Record Verification Date:
2023/02/13
Next update date:
2024/02/13
Link to the spanish version:
Click here
Acerca del RPCEC
Estructura y Gobernanza
Política
Publicaciones
Reconocimientos
Comunicaciones
Noticias
Recursos útiles
Fundamentos del registro
Bibliografías en ensayos clínicos
Regulaciones cubanas
Otros registros
Plataforma Internacional de Registros de Ensayos Clínicos